Caribou Q4 net loss $27M; cash $317M; CB-010 data update planned H2 2023

Caribou Biosciences, Inc.

Net loss of $27.0M in Q4 2022 and $99.4M for full year 2022, vs. $18.5M and $66.9M in 2021.
Cash, equivalents, and marketable securities $317.0M as of Dec 31, 2022; runway into 2025.
CB-010 ANTLER trial: all 6 pts at dose level 1 achieved complete response; 6-month CR in 3/6.
CB-011 CaMMouflage trial recruiting at dose level 1 for r/r multiple myeloma; CB-012 IND planned H2 2023.
R&D expenses $25.7M in Q4 2022 vs. $15.1M in Q4 2021, driven by pipeline advancement and headcount.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Caribou Biosciences, Inc. reported financial results for the fourth quarter and year ended December 31, 2022.

Period: the fourth quarter and year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 9, 2023, Caribou Biosciences, Inc., a Delaware corporation (the “Company”), issued a press release announcing the Company’s financial results for the fourth quarter and year ended December 31, 2022 and providing a business update.

View on SEC.gov

Browse all earnings releases →

Caribou Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001619856-23-000035

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.